Summary

Tristel plc (AIM: TSTL) delivered full-year revenue of £51.1m for the year to 30 June 2026, up roughly 10% on the prior year’s £46.5m. The AIM-listed infection-prevention specialist uses proprietary chlorine dioxide chemistry to decontaminate medical devices and disinfect surfaces in hospitals worldwide. Can infection-control demand fuel another strong year? The recurring, largely non-discretionary nature of its sales, combined with early momentum in the United States, makes continued growth plausible — but a leadership change and execution risk mean nothing is guaranteed.

Key Takeaways

  • Tristel plc (TSTL) reported FY26 revenue of £51.1m, an increase of about 10% on FY25’s £46.5m and consistent with its long-run double-digit growth ambition.
  • Around 98% of revenue comes from consumable products performing essential, non-discretionary infection-control functions, giving the business unusually resilient, recurring demand.
  • The United States is the key growth frontier, with FDA-cleared products, engagement across roughly 200 health systems and a distribution partnership with Parker Laboratories.
  • A leadership transition is under way: chief executive Matt Sassone departed at the end of June 2026, with Chris Lee due to take over from 1 August 2026 and CFO Anna Wasyl acting as interim CEO.
  • The business is debt-free, highly cash-generative and high-margin, but its premium rating and US execution risk warrant a balanced view.

Who is Tristel (TSTL), and how does its chlorine dioxide technology work?

Tristel plc is a global infection-prevention company listed on London’s AIM market under the ticker TSTL, where it has traded since 2005. Its head office and manufacturing site are at Snailwell, near Cambridge, and it employs around 270 people across roughly 16 subsidiaries, selling into more than 40 countries.

The company’s edge is proprietary chlorine dioxide (ClO2) chemistry — a powerful, broad-spectrum biocide that Tristel delivers in formulations, often foams, that are effective, quick to use and gentle on delicate instruments. This underpins two activities: manual decontamination of medical devices, sold under the Tristel brand and accounting for most revenue, and sporicidal surface disinfection, offered as a more sustainable alternative to pre-wetted plastic wipes. A smaller division serves pharmaceutical, personal-care, veterinary and animal-welfare markets.

Crucially, hospitals use these products every day. Over 98% of Tristel’s revenue comes from consumables performing essential, non-discretionary functions — cleaning ultrasound probes, endoscopes and other reusable instruments between patients. That recurring, compliance-driven demand is the foundation of the investment case.

What did Tristel announce, and what does £51.1m of FY26 revenue represent?

The headline is full-year revenue of £51.1m for the year ended 30 June 2026, growth of approximately 10% over FY25’s £46.5m and an extension of a long record of double-digit or near-double-digit expansion. Figures released shortly after a year-end are typically unaudited and precede the full accounts, so £51.1m should be treated as a headline number pending the detailed report expected later in the year.

This growth reflects the steady accumulation of hospital accounts, deeper penetration of existing customers and geographic expansion. In the first half (the six months to 31 December 2025), Tristel reported revenue up 14% year on year, with gross margin at 81% and adjusted EBITDA margin of 29% — comfortably ahead of its “at least 25%” target. The full-year outcome confirms momentum carried through the second half, even if the annual growth rate settled at around 10%.

For context, the company targets double-digit annual revenue growth, an adjusted EBITDA margin of at least 25%, and a progressive dividend underpinned by strong cash generation. The FY26 revenue figure keeps the first of those broadly on track.

Which numbers matter most in Tristel’s results?

Revenue growth is the headline, but Tristel’s quality shows elsewhere. In FY25, gross margin was around 81%, adjusted pre-tax profit rose 23% to £10.1m, and the business was strongly cash-generative and debt-free (aside from lease liabilities). Cash and cash equivalents stood at roughly £8.6m at the FY25 year-end, up from about £6.1m a year earlier — healthy for a company of its size and consistent with its cash-generative model.

Three metrics deserve attention. Gross margin, at roughly 81%, reflects proprietary chemistry and pricing power, and its stability signals that growth is not being bought through discounting. The adjusted EBITDA margin, at 29% in the first half, shows profitability scaling faster than costs. And in FY25 most of the revenue increase came from higher volumes rather than price rises, suggesting genuine adoption rather than one-off pricing actions.

These are the numbers that separate durable compounders from companies flattered by temporary tailwinds. They are historic figures, however, and do not guarantee margins or cash generation will be sustained.

Why does resilient infection-control demand matter for Tristel (TSTL)?

Infection prevention is not optional. Hospitals must decontaminate reusable medical devices between patients whatever the economic climate, which insulates Tristel (TSTL) from much of the cyclicality affecting discretionary healthcare spending. When a product is consumed with every procedure and is central to patient safety and compliance, demand tends to be steady and repeat purchasing high.

This matters for two reasons: a large installed base reorders consumables predictably, giving revenue visibility; and because switching disinfection protocols is disruptive and clinically sensitive, hospitals are reluctant to change suppliers, which supports pricing. Together, these features explain Tristel’s consistent growth and protected margins.

The flip side is that growth still depends on winning new accounts and expanding into new procedures and geographies. Resilient demand underpins the base business but does not, by itself, deliver the double-digit growth the company aspires to — which is why expansion, above all in the US, is so important.

How has Tristel performed over recent years?

Tristel’s recent trajectory has been one of steady, profitable growth. Revenue climbed from £31.1m in FY2022 to £46.5m in FY2025 — a compound annual growth rate of around 14% — and reached £51.1m in FY2026. Along the way it has expanded its direct sales footprint, adding markets such as Spain, India and Austria, and continued to convert its technology into new, regulator-cleared products.

Profitability has broadly tracked revenue, with adjusted profit rising and margins holding firm, and the dividend has been progressive. This combination — reliable growth, high margins, cash generation and a rising dividend — is why Tristel has long been regarded as a quality name on AIM.

Past performance is not a reliable guide to what comes next, and the company is now navigating a leadership change while scaling up in a demanding new market.

What is happening in the infection-prevention market?

The structural backdrop is supportive. Ageing populations, rising procedure volumes, greater awareness of healthcare-associated infections and tightening decontamination standards all point to sustained demand for infection control. Sustainability pressures are an added tailwind for Tristel’s Cache surface range, a greener alternative to single-use plastic wipes.

Regulatory recognition is a recurring theme. Tristel has highlighted the inclusion of chlorine dioxide foam in updated US disinfection standards and independent clinical evidence with leading institutions, including work associated with the Mayo Clinic. Such endorsements matter where clinicians and procurement teams demand robust proof of efficacy before adopting new protocols.

Competition is real, however. Tristel operates against larger disinfection and medical-device businesses, and hospital purchasing can be slow and consensus-driven. The opportunity is large and growing, but capturing it requires patient, evidence-led selling.

Can US expansion fuel another strong year for Tristel (TSTL)?

The United States is the single biggest swing factor — the world’s largest healthcare market, which Tristel has spent years securing approvals to enter. Its US ultrasound-probe disinfectant, sold as Tristel ULT and based on the same chlorine dioxide foam family as its Duo products, reached the market via the FDA’s De Novo pathway for genuinely novel devices. It has since added FDA 510(k) clearance for Tristel OPH, a high-level disinfectant for ophthalmic instruments addressing around 16 million procedures a year in North America, while Environmental Protection Agency registration underpins its surface-disinfection ambitions.

Commercially, Tristel has partnered with Parker Laboratories, whose nationwide sales force is helping to seed the ULT product. It reports engagement across roughly 200 US health systems, with the priority now shifting from generating leads to driving deeper adoption and recurring reorders. Management has said US revenue growth is in line with internal forecasts.

If that engagement converts into sustained, recurring consumable sales, the US could become a meaningful contributor to group revenue — the clearest route to “another strong year” and beyond. The word to stress is if: early interest is encouraging, but scaling adoption in a large, complex market is a multi-year effort, and the pace and profitability of that ramp-up are not guaranteed.

What leadership change is under way at Tristel?

Investors should note a significant transition at the top. Chief executive Matt Sassone, who joined in 2024, announced in January 2026 that he would resign for a worldwide president role at a large US multinational, and left at the end of June 2026. The board appointed Christopher (“Chris”) Lee as chief executive with effect from 1 August 2026, following a competitive process; chief financial officer Anna Wasyl is acting as interim CEO, and the chair is Bruno Holthof.

Chris Lee brings more than 35 years in medical technology and healthcare, including chief-executive roles at Summit Medical and Venner Medical International and senior positions at Teleflex, LMA and Johnson & Johnson. His extensive US experience is directly relevant to Tristel’s central growth priority.

Leadership change always carries some risk to continuity, but the depth of the management team and the incoming CEO’s sector experience should help smooth the handover. The strategy — double-digit growth, high margins and US expansion — is expected to remain unchanged.

What are the principal risks for Tristel (TSTL)?

Several risks temper the optimism. US expansion, while promising, is unproven at scale; adoption could prove slower or less profitable than hoped, and reliance on a distribution partner adds a layer the company does not fully control. The leadership transition, though well managed, introduces execution and continuity risk at a pivotal moment.

Beyond that, Tristel faces competition from larger players, potential pricing pressure, regulatory and quality-compliance demands across many jurisdictions, and currency movements given its international footprint. As a specialist AIM company, its shares can be more volatile and less liquid than larger peers’, and any disappointment against high expectations can prompt sharp moves. Capital is at risk, and the strengths described here do not rule out a weaker year.

How is Tristel valued?

Tristel has historically commanded a premium, growth-style rating, reflecting its high margins, recurring revenue, cash generation and long growth record. Precise current valuation multiples and market capitalisation are not confirmed in this article and should be checked against up-to-date market data before drawing conclusions.

The key point is that a premium rating raises the bar: it prices in continued execution, especially in the US. If growth and margins hold, the rating can be justified; if the US ramp-up stalls or margins slip, a highly rated share has further to fall. Valuation is therefore both a reflection of quality and a source of risk, and sector comparisons should use current figures rather than assumptions.

What is the balanced outlook for Tristel?

Tristel plc (TSTL) heads into its new financial year with genuine momentum: FY26 revenue of £51.1m, resilient and recurring infection-control demand, expanding margins, a debt-free balance sheet and an increasingly credible US opportunity. The building blocks for another good year are in place.

Set against that are a leadership change, the unproven economics of US scale-up, competition and a premium valuation that leaves little room for disappointment. Can infection-control demand fuel another strong year? On the evidence, continued growth is plausible — but not certain, and prudent investors will watch US adoption and the CEO transition closely rather than assume the trajectory continues.

Conclusion

Tristel plc (TSTL) has delivered another year of growth, with FY26 revenue of £51.1m built on resilient, recurring infection-control demand and disciplined execution. Its high margins, cash generation and expanding US presence make the case that further growth is achievable. Yet a leadership transition and the unproven economics of scaling in the United States mean the outcome is not assured, and the premium rating leaves limited margin for error. The direction is encouraging, but investors should weigh the risks and reach their own conclusions.